Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267831 | 1.00 | HTR2A (0.38) | HTR2ACYP2C19ALOX5MAOADPP4 | |
| SCHEMBL13056306 | 0.82 | DPP4 (0.36) | ALOX5MAOADPP4MEN1KMT2A | |
| SCHEMBL13056307 | 0.82 | DPP4 (0.36) | ALOX5MAOADPP4MEN1KMT2A | |
| SCHEMBL17300289 | 0.81 | DPP4 (0.56) | DPP4ALDH1A1 | |
| SCHEMBL8634102 | 0.81 | DPP4 (0.56) | DPP4ALDH1A1 | |
| SCHEMBL17300288 | 0.81 | DPP4 (0.56) | DPP4ALDH1A1 | |
| SCHEMBL2996389 | 0.77 | CYP1A2 (0.44) | CYP2C19MAOASMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL13267800 | 0.77 | CYP1A2 (0.44) | CYP2C19MAOASMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL2996386 | 0.77 | CYP1A2 (0.44) | CYP2C19MAOASMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL3749883 | 0.77 | CYP1A2 (0.44) | CYP2C19MAOASMN1; SMN2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | HNMT, AADAT, DAO | HTR2A 1380/4885CYP2C19 281/4885ALOX5 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.